Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2019

Open Access 01.12.2019 | Research

Laparoscopic gastrectomy with and without prophylactic drains in gastric cancer: a propensity score-matched analysis

verfasst von: Norihiro Shimoike, Shin Akagawa, Daisuke Yagi, Masazumi Sakaguchi, Yukinari Tokoro, Eiichiro Nakao, Takuya Tamura, Yusuke Fujii, Yuki Mochida, Yoshihisa Umemoto, Hidero Yoshimoto, Seiichiro Kanaya

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2019

Abstract

Background

The number of patients who are undergoing laparoscopic gastrectomy for treating gastric cancer is increasing. Although prophylactic drains have been widely employed following the procedure, there are few studies reporting the efficacy of prophylactic drainage. Therefore, this study assessed the efficacy of prophylactic drains following laparoscopic gastrectomy for gastric cancer.

Methods

Data of patients who received laparoscopic gastrectomy for treating gastric cancer in our institution between April 2011 and March 2017 were reviewed, and the outcomes of patients with and without a prophylactic drainage were compared. Propensity score matching was used to minimize potential selection bias.

Results

A total of 779 patients who underwent surgery for gastric cancer were reviewed; of these, 628 patients who received elective laparoscopic gastrectomy were included in this study. After propensity score matching, data of 145 pairs of patients were extracted. No significant differences were noted in the incidence of postoperative complications between the drain and no-drain groups (19.3% vs 11.0%, P = 0.071). The days after the surgery until the initiation of soft diet (6.3 ± 7.4 vs 4.9 ± 2.9 days, P = 0.036) and the length of postoperative hospital stay (15.7 ± 12.9 vs 13.0 ± 6.3 days, P = 0.023) were greater in the drain group than those in the no-drain group.

Conclusions

This study suggests that routinely using prophylactic drainage following laparoscopic gastrectomy for treating gastric cancer is not obligatory.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
EGJ
Esophagogastric junction
RCTs
Randomized controlled trials

Background

Prophylactic abdominal drains have been widely employed following gastrointestinal surgeries. After gastric cancer surgery, prophylactic drains were used in 57.7 to 62.8% of the patients in observational studies [1, 2] and routinely used in a randomized controlled trial (RCT) [3]. The purpose of the prophylactic drain is to remove intra-abdominal fluid collections and to detect postoperative complications such as anastomotic leakage, intra-abdominal bleeding, and intra-abdominal abscess. Another potential function of prophylactic drains is in therapeutic drainage in cases of such complications. However, the rates of postoperative morbidity and mortality have decreased due to advances in surgical techniques and perioperative care. Therefore, the disadvantages of prophylactic drains have been questioned of late.
A previous investigation revealed that prophylactic drains do not reduce complications following hepatectomy, colorectal resection, and appendectomy [4]. Moreover, drains were demonstrated to be even harmful after hepatectomy in chronic liver disease and appendectomy [4]. Regarding gastrectomy, few studies have investigated prophylactic drainage [47]. However, data regarding prophylactic drainage after laparoscopic gastrectomy are minimal [1, 8].
Therefore, this study aimed to evaluate the effect of prophylactic drains after laparoscopic gastrectomy for treating gastric cancer.

Methods

Participants

We reviewed patients who received gastrectomy for histologically confirmed gastric cancer in our institution between April 2011 and March 2017. Those who underwent open surgery or proximal gastrectomy with lower esophagectomy for esophagogastric junction (EGJ) cancer were excluded. In addition, patients who received simultaneous complicated surgery for other organ diseases were excluded. The outcomes of patients who received laparoscopic gastrectomy with and without prophylactic drainage were compared. Propensity score matching was used to minimize potential selection bias.

Operative indication and procedure

All radical surgeries for treating gastric cancer were performed laparoscopically irrespective of the clinical stage, unless an emergent situation such as perforation or acute bleeding existed.
The extent of gastrectomy and lymph node dissection was determined based on the Japanese gastric cancer treatment guidelines [9, 10]. A splenectomy was performed when the tumor was found to be located on the greater curvature of the upper third of the stomach. Moreover, combined resection of other organs such as distal pancreatectomy, transverse colectomy, and partial hepatectomy was performed when cancer involvement was suspected and when R0 resection was possible.
All reconstruction procedures were intracorporeally performed. Billroth I using delta-shaped anastomosis [11] and Roux-en-Y using a functional end-to-end method [12, 13] were the preferred choices of reconstruction procedures after distal and total gastrectomies, respectively.
The decision to use a prophylactic drain was made by the surgeon. After January 2015, drains were not used in principle owing to the low incidence of postoperative complications. However, in case of drain requirement, a closed passive drain was used.
Operations were performed by or under the guidance of qualified surgeons registered in the Japanese Society for Endoscopic Surgery [14].

Surgical outcome assessment

Surgical outcomes in this study included operative mortality, the incidence of postoperative complications, the number of days after the surgery until the initiation of a soft diet, and the length of postoperative hospital stay. Postoperative complications included any adverse events determined as grade II or more using the Clavien–Dindo classification within 30 days after the surgery. Operative mortality was defined as death occurring within 30 days after the surgery.

Statistical analysis

All statistical analyses were performed using R version 3.3.2 (the R foundation for statistical computing, Vienna, Austria). Intergroup comparisons were performed using Student’s t test for continuous variables and two-tailed χ2 test for discrete variables. Statistical significance was set a priori at P < 0.05.
Propensity score was calculated using a multiple logistic regression model for the variables shown in Table 1. Propensity score matching was then conducted by nearest-neighbor matching without replacement with an algorithm of 1:1 matching. A caliper width of 0.25 of the standard deviation of the logit of the propensity score was used.
Table 1
Demographic and perioperative characteristics before and after propensity score matching
 
Before propensity score matching
After propensity score matching
Drain
No drain
P value
Drain
No drain
P value
(n = 327)
(n = 301)
(n = 145)
(n = 145)
Sex, n (%)
  
0.048
  
0.613
 Male
237 (72.5)
196 (65.1)
 
102 (70.3)
97 (66.9)
 
 Female
90 (27.5)
105 (34.9)
 
43 (29.7)
48 (33.1)
 
Age, mean ± SD, years
68.8 ± 10.0
69.2 ± 11.3
0.629
68.3 ± 10.7
68.4 ± 11.6
0.937
Body mass index (BMI), mean ± SD
22.7 ± 3.4
22.6 ± 3.0
0.527
22.7 ± 3.1
22.6 ± 2.9
0.895
Performance status (ECOG), n (%)
  
0.284
  
0.966
 0
193 (59.0)
158 (52.5)
 
88 (60.7)
88 (60.7)
 
 1
112 (34.3)
114 (37.9)
 
46 (31.7)
44 (30.3)
 
 2
21 (6.4)
26 (8.6)
 
11 (7.6)
12 (8.3)
 
 3
1 (0.3)
3 (1.0)
 
0 (0)
1 (0.7)
 
Comorbidity, n (%)
 Ischemic heart disease
27 (8.3)
17 (5.6)
0.214
8 (5.5)
10 (6.9)
0.809
 Heart failure
2 (0.6)
4 (1.3)
0.434
1 (0.7)
1 (0.7)
1
 Hypertension
127 (38.8)
120 (39.9)
0.807
57 (39.3)
60 (41.4)
0.811
 Diabetes mellitus
51 (15.6)
43 (14.3)
0.656
22 (15.2)
21 (14.5)
1
 Chronic hepatitis/cirrhosis
20 (6.1)
6 (2.0)
0.015
3 (2.1)
5 (3.4)
0.723
 Hemodialysis
2 (0.6)
2 (0.7)
1
0 (0)
1 (0.7)
1
 Ventilatory impairment
69 (21.1)
58 (19.3)
0.619
29 (20.0)
25 (17.2)
0.651
 Regular steroid use
9 (2.8)
3 (1.0)
0.146
4 (2.8)
3 (2.1)
1
 Anti-thrombotic therapy
47 (14.4)
34 (11.3)
0.284
17 (11.7)
21 (14.5)
0.602
 History of abdominal surgery
122 (37.3)
105 (34.9)
0.561
57 (39.3)
51 (35.2)
0.544
Depth of invasion, n (%)
  
< 0.001
  
0.943
 cT1
125 (38.2)
180 (59.8)
 
80 (55.2)
75 (51.7)
 
 cT2
60 (18.3)
53 (17.6)
 
24 (16.6)
26 (17.9)
 
 cT3
62 (19.0)
33 (11.0)
 
19 (13.1)
19 (13.1)
 
 cT4
80 (24.5)
35 (11.6)
 
22 (15.2)
25 (17.2)
 
Node metastasis, n (%)
  
< 0.001
  
0.48
 cN0
230 (70.3)
253 (84.1)
 
118 (81.4)
112 (77.2)
 
 cN1
48 (14.7)
24 (8.0)
 
10 (6.9)
17 (11.7)
 
 cN2
39 (11.9)
20 (6.6)
 
12 (8.3)
13 (9.0)
 
 cN3
10 (3.1)
4 (1.3)
 
5 (3.4)
3 (2.1)
 
Preoperative chemotherapy, n (%)
26 (8.0)
13 (4.3)
0.069
9 (6.2)
9 (6.2)
1
Operative procedure, n (%)
  
< 0.001
   
 Distal gastrectomy (DG)
173 (52.9)
256 (85.0)
 
104 (71.7)
109 (75.2)
 
 Total gastrectomy (TG)
134 (41.0)
40 (13.3)
 
34 (23.4)
32 (22.1)
 
 Remnant gastrectomy
20 (6.1)
5 (1.7)
 
7 (4.8)
4 (2.8)
 
Extent of lymphadenectomy, n (%)
  
< 0.001
  
0.878
 DG D1+ or less
86 (26.3)
167 (55.5)
 
58 (40.0)
63 (43.4)
 
 DG D2
87 (26.6)
89 (29.6)
 
46 (31.7)
46 (31.7)
 
 TG D1+ or less
115 (35.2)
43 (14.3)
 
38 (26.2)
34 (23.4)
 
 TG D2
39 (11.9)
2 (0.7)
 
3 (2.1)
2 (1.4)
 
Combined resection of other organs, n (%)
40 (12.2)
4 (1.3)
< 0.001
3 (2.1)
2 (1.4)
1
Type of reconstruction, n (%)
  
< 0.001
  
0.923
 Billroth I
108 (33.0)
189 (62.8)
 
74 (51.0)
80 (55.2)
 
 Billroth II
44 (13.5)
45 (15.0)
 
19 (13.1)
20 (13.8)
 
 Roux-en-Y (DG)
22 (6.7)
22 (7.3)
 
11 (7.6)
9 (6.2)
 
 Roux-en-Y (TG; functional end-to-end)
101 (30.9)
40 (13.3)
 
34 (23.4)
31 (21.4)
 
 Roux-en-Y (TG; overlap)
51 (15.6)
5 (1.7)
 
7 (4.8)
5 (3.4)
 
 Roux-en-Y (TG; circular stapler)
1 (0.3)
0 (0)
 
0 (0)
0 (0)
 
R status, n (%)
  
0.004
  
0.195
 R0
286 (87.5)
285 (94.7)
 
139 (95.9)
132 (91.0)
 
 R1
24 (7.3)
7 (2.3)
 
2 (1.4)
7 (4.8)
 
 R2
17 (5.2)
9 (3.0)
 
4 (2.8)
6 (4.1)
 
Blood loss, mean ± SD, ml
52.7 ± 138.3
18.7 ± 62.0
< 0.001
22.5 ± 72.1
26.8 ± 80.8
0.634
Operation time, mean ± SD, min
349 ± 78
268 ± 62
< 0.001
308 ± 57
304 ± 62
0.598

Results

A total of 779 patients who underwent surgery for gastric cancer were reviewed. Of these, 45 patients who underwent proximal gastrectomy for EGJ cancer, 83 who underwent open gastrectomy (including four cases converted from laparoscopic surgery), and 21 who underwent a simultaneous surgery for other diseases such as colorectal cancer (n = 14), hepatic cancer (n = 1), familial adenomatous polyposis (n = 1), choledocholithiasis (n = 1), breast cancer (n = 2), ovarian tumor (n = 1), and malignant lymphoma of the cecum (n = 1) were excluded. One patient who underwent emergent laparoscopic surgery for a gastric cancer perforation and one patient with insufficient clinical data on our database were also excluded.
Thus, 628 patients who received elective laparoscopic gastrectomy were enrolled in this study. In this cohort, prophylactic drain was used for 327 patients (52.1%). Table 1 shows the perioperative characteristics of the patients with (drain group) and without a drain (no-drain group). Significant differences were noted between the two groups with respect to sex, chronic liver disease, clinical T and N stages, the extent of gastrectomy and lymphadenectomy, combined resection of other organs, the type of reconstruction, the amount of blood loss, the length of the operation time, and R status. Table 2 shows the outcomes among patients with each characteristic in whole enrolled population.
Table 2
Outcomes among patients with each characteristic before propensity score matching
 
Postoperative complication ≥grade II*
Postoperative complication ≥grade III*
Initiation of soft diet (days)
Postoperative hospital stay (days)
Drain
No drain
Drain
No drain
Drain
No drain
Drain
No drain
n (%)
n (%)
n (%)
n (%)
Median (range)
Median (range)
Median (range)
Median (range)
Depth of invasion
 cT1 (n = 125 vs 180)
33 (26.4)
22 (12.2)
9 (7.2)
2 (1.1)
5 (3–47)
4 (3–33)
13 (7–82)
11 (3–65)
 cT2 (n = 60 vs 53)
15 (25.0)
7 (13.2)
7 (11.7)
1 (1.9)
5 (3–44)
4 (3–45)
11.5 (8–104)
12 (7–57)
 cT3 (n = 62 vs 33)
12 (19.4)
4 (12.1)
3 (4.8)
0 (0)
5 (3–29)
5 (3–18)
13 (8–92)
13 (6–56)
 cT4 (n = 80 vs 35)
18 (22.5)
5 (14.3)
3 (3.8)
1 (2.9)
5 (3–81)
4 (3–67)
14 (9–114)
11 (4–90)
Node metastasis
 cN0 (n = 230 vs 253)
59 (25.7)
32 (12.6)
16 (7.0)
3 (1.2)
5 (3–54)
4 (3–45)
13 (7–82)
12 (3–65)
 cN1 (n = 48 vs 24)
12 (25.0)
3 (12.5)
5 (10.4)
0 (0)
5 (3–30)
4 (3–8)
13 (10–104)
11.5 (6–30)
 cN2 (n = 39 vs 20)
6 (15.4)
2 (10.0)
0 (0)
1 (5.0)
5 (3–31)
5 (3–67)
12 (9–60)
11.5 (4–90)
 cN3 (n = 10 vs 4)
1 (10.0)
1 (25.0)
1 (10.0)
0 (0)
4.5 (3–81)
3.5 (3–5)
13.5 (10–114)
11.5 (10–27)
Operative procedure
 Distal gastrectomy (DG) (n = 173 vs 256)
34 (19.7)
33 (12.9)
8 (4.6)
4 (1.6)
4 (3–54)
4 (3–67)
12 (7–59)
11 (4–90)
 Total gastrectomy (TG) (n = 134 vs 40)
36 (26.9)
5 (12.5)
12 (9.0)
0 (0)
5 (3–81)
5 (3–18)
12 (8–114)
12 (4–56)
 Remnant gastrectomy (n = 20 vs 5)
8 (40.0)
0 (0)
2 (10.0)
0 (0)
6.5 (4–22)
5 (3–5)
16.5 (9–82)
11 (3–12)
Extent of lymphadenectomy
 DG D1+ or less (n = 86 vs 167)
19 (22.1)
24 (14.4)
5 (5.8)
4 (2.4)
5 (3–21)
4 (3–67)
12 (9–52)
11 (4–90)
 DG D2 (n = 87 vs 89)
15 (17.2)
9 (10.1)
3 (3.4)
0 (0)
4 (3–54)
4 (3–12)
11 (7–59)
12 (6–34)
 TG D1+ or less (n = 115 vs 43)
31 (27.0)
4 (9.3)
11 (9.6)
0 (0)
5 (3–44)
5 (3–18)
13 (8–92)
12 (3–56)
 TG D2 (n = 39 vs 2)
13 (33.3)
1 (50.0)
3 (7.7)
0 (0)
6 (3–81)
6 (5–7)
14 (9–114)
14 (14–14)
R status
 R0 (n = 286 vs 285)
67 (23.4)
36 (12.6)
18 (6.3)
3 (1.1)
5 (3–47)
4 (3–45)
13 (7–92)
12 (3–65)
 R1 (n = 24 vs 7)
5 (20.8)
0 (0)
2 (8.3)
0 (0)
5.5 (3–54)
4 (3–6)
13.5 (9–104)
13 (10–34)
 R2 (n = 17 vs 9)
6 (35.3)
2 (22.2)
2 (11.8)
1 (11.1)
6 (4–81)
4 (3–67)
16 (10–114)
11 (4–90)
Blood loss
 < 500 ml (n = 322 vs 300)
77 (23.9)
38 (12.7)
22 (6.8)
4 (1.3)
5 (3–81)
4 (3–67)
13 (7–114)
11.5 (3–90)
 ≥ 500 ml (n = 5 vs 1)
1 (20.0)
0 (0)
0 (0)
0 (0)
6 (4–21)
7
13 (11–31)
13
*Clavien–Dindo classification
After propensity score matching, data of 145 pairs of patients were extracted. The flow chart of patients assessed in this study is shown in Fig. 1. Perioperative characteristics after propensity score matching are additionally indicated in Table 1. No significant differences were noted in perioperative characteristics between the drain and no-drain groups after propensity score matching.
Table 3 shows the primary outcomes of this study. No significant differences were noted in the incidence of postoperative complications between the drain and no-drain groups (19.3% vs 11.0%, P = 0.071). The number of days after surgery until the initiation of soft diet (6.3 ± 7.4 vs 4.9 ± 2.9 days, P = 0.036) and the length of postoperative hospital stay (15.7 ± 12.9 vs 13.0 ± 6.3 days, P = 0.023) were greater in the drain group than in the no-drain group. No hospital deaths were observed within 30 days after surgery; three and one patients in the drain and no-drain groups, respectively, had complications that required reoperation within 30 days after the surgery. The breakdown of postoperative complications is shown in Table 4.
Table 3
Comparison of surgical outcomes between the drain and no drain groups in the matched cohort
 
Drain (n = 145)
No drain (n = 145)
P value
Postoperative complications ≥grade II*, n (%)
28 (19.3)
16 (11.0)
0.071
Postoperative complications ≥grade III*, n (%)
8 (5.5)
3 (2.1)
0.218
Initiation of soft diet, mean ± SD, days
6.3 ± 7.4
4.9 ± 2.9
0.036
Postoperative hospital stay, mean ± SD, days
15.7 ± 12.9
13.0 ± 6.3
0.023
*Clavien–Dindo classification
Table 4
Postoperative complications in the drain and no drain groups in the matched cohort
 
Drain (n = 145)
No drain (n = 145)
Grade II*
 Anastomotic leakage
2
1
 Pancreatic fistula
6
1
 Intra-abdominal abscess
2
3
 Intra-abdominal bleeding
1
0
 Ileus
1
0
 Chylous ascites
1
1
 Pneumonia
2
2
 Delayed gastric emptying
0
1
 Liver injury
2
1
 Fever of unknown origin
1
2
 Pseudomembranous colitis
0
1
 Wound infection
1
0
 Catheter-related infection
1
0
Grade III*
 Anastomotic leakage
3
0
 Pancreatic fistula
2
1
 Ileus
1
1
 Pleural effusion
0
1
 Anastomotic stenosis
1
0
 Hepatorenal insufficiency
1
0
30-day mortality
0
0
Reoperation
3
1
*Clavien–Dindo classification

Discussion

The results of the present study do not support the routine use of prophylactic drains following laparoscopic gastrectomy. Prophylactic drains are typically used for the early detection and prevention of the aggravation of postoperative complications. The present study, however, revealed no significant differences between the incidence and the severity of postoperative complications. Rather, complications tended to occur in the drain group. Moreover, in the drain group, the number of days after surgery until the initiation of soft diet and postoperative hospital stay were greater than those in the no-drain group, suggesting that drains do not additionally benefit or may even prove to be harmful for managing postoperative complications.
Few studies have been reported on the clinical value of prophylactic drains following surgeries for gastric cancer. Petrowsky et al. reported that the use of drains after total gastrectomy is justified because anastomotic leakage after total gastrectomy can cause life-threatening mediastinitis [4]; however, these conclusions were not based on comparative studies. We found three randomized controlled trials (RCTs) comparing drain use and no-drain use in patients who underwent gastrectomy [57]; however, none of the trials supported the use of prophylactic drainage after a subtotal or total gastrectomy.
Similarly, data regarding the use of prophylactic drains after laparoscopic gastrectomy is limited [1, 8], and to the best of our knowledge, there are no RCTs evaluating this use of prophylactic drains. Since Kitano et al. reported the first laparoscopy-assisted gastrectomy in 1994 [15], the number of patients that are being treated using the laparoscopic technique is increasing [16]. The safety associated with the use of laparoscopic gastrectomy is of great concern; however, advances in operative techniques and laparoscopic instruments have led to the standardization of laparoscopic gastrectomy, and its overall safety is gradually being clarified [1719]. Considering the low incidence of postoperative complications (5.1–11.6%), the necessity of prophylactic drains should be evaluated.
In the present study, we included almost all patients with gastric cancer who were treated using laparoscopic gastrectomy, regardless of their comorbidity, the clinical stage of cancer, and the extent of the surgery. This comprehensive inclusion is more likely to reflect actual clinical settings. To minimize the risk of confounding variables, propensity score matching was used. Although RCTs have been considered the gold standard for therapeutic evaluation, assessing surgical procedures in RCTs raises several methodological and practical challenges for surgical research [20]. Recently, a study comparing the effects of treatment estimated from observational studies using propensity score analysis and those from RCTs performed for the same clinical question in the surgical field revealed no statistically significant differences [21]. However, this study contains a limitation due to historical nature of the study design. Since we changed the indication of prophylactic drains during the study period, drains were more likely to be placed to the patients who received surgery in the early period. Therefore, potential improvement in surgical technique and perioperative care during the study period may affect the outcomes. Even considering such a historical effect, omitting prophylactic drains was safe without increased morbidity.

Conclusion

In conclusion, this study suggests that the routine use of prophylactic drainage after laparoscopic gastrectomy for gastric cancer is not always necessary, although caution should be exercised when making clinical decisions owing to the retrospective design of this study.

Acknowledgements

We thank Enago editing services for the excellent language editing.

Disclosures

Drs. Shimoike, Akagawa, Yagi, Sakaguchi, Tokoro, Nakao, Tamura, Fujii, Mochida, Umemoto, Yoshimoto, Kanaya have no conflicts of interest or financial ties to disclose.
This study was approved by the institutional review board of Osaka Red Cross Hospital. All patient procedures were performed after obtaining written informed consent.
Not applicable

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Hirahara N, Matsubara T, Hayashi H, Takai K, Fujii Y, Tajima Y. Significance of prophylactic intra-abdominal drain placement after laparoscopic distal gastrectomy for gastric cancer. World J Surg Oncol. 2015;13:181.CrossRef Hirahara N, Matsubara T, Hayashi H, Takai K, Fujii Y, Tajima Y. Significance of prophylactic intra-abdominal drain placement after laparoscopic distal gastrectomy for gastric cancer. World J Surg Oncol. 2015;13:181.CrossRef
2.
Zurück zum Zitat Lee J, Choi YY, An JY, Seo SH, Kim DW, Seo YB, Nakagawa M, Li S, Cheong JH, Hyung WJ, Noh SH. Do all patients require prophylactic drainage after gastrectomy for gastric cancer? The experience of a high-volume center. Ann Surg Oncol. 2015;22:3929–37.CrossRef Lee J, Choi YY, An JY, Seo SH, Kim DW, Seo YB, Nakagawa M, Li S, Cheong JH, Hyung WJ, Noh SH. Do all patients require prophylactic drainage after gastrectomy for gastric cancer? The experience of a high-volume center. Ann Surg Oncol. 2015;22:3929–37.CrossRef
3.
Zurück zum Zitat Shi Y, Xu X, Zhao Y, Qian F, Tang B, Hao Y, Luo H, Chen J, Yu P. Short-term surgical outcomes of a randomized controlled trial comparing laparoscopic versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer. Surg Endosc. 2018;32:2427–33.CrossRef Shi Y, Xu X, Zhao Y, Qian F, Tang B, Hao Y, Luo H, Chen J, Yu P. Short-term surgical outcomes of a randomized controlled trial comparing laparoscopic versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer. Surg Endosc. 2018;32:2427–33.CrossRef
4.
Zurück zum Zitat Petrowsky H, Demartines N, Rousson V, Clavien PA. Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses. Ann Surg. 2004;240:1074–85.CrossRef Petrowsky H, Demartines N, Rousson V, Clavien PA. Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses. Ann Surg. 2004;240:1074–85.CrossRef
5.
Zurück zum Zitat Kim J, Lee J, Hyung WJ, Cheong JH, Chen J, Choi SH, Noh SH. Gastric cancer surgery without drains: a prospective randomized trial. J Gastrointest Surg. 2004;8:727–32.CrossRef Kim J, Lee J, Hyung WJ, Cheong JH, Chen J, Choi SH, Noh SH. Gastric cancer surgery without drains: a prospective randomized trial. J Gastrointest Surg. 2004;8:727–32.CrossRef
6.
Zurück zum Zitat Kumar M, Yang SB, Jaiswal VK, Shah JN, Shreshtha M, Gongal R. Is prophylactic placement of drains necessary after subtotal gastrectomy? World J Gastroenterol. 2007;13:3738–41.CrossRef Kumar M, Yang SB, Jaiswal VK, Shah JN, Shreshtha M, Gongal R. Is prophylactic placement of drains necessary after subtotal gastrectomy? World J Gastroenterol. 2007;13:3738–41.CrossRef
7.
Zurück zum Zitat Alvarez UR, Molina H, Torres O, Cancino A. Total gastrecyomy with or without abdominal drains: a prospective randomized trial. Rev Esp Enferm Dig. 2005;97:562–9. Alvarez UR, Molina H, Torres O, Cancino A. Total gastrecyomy with or without abdominal drains: a prospective randomized trial. Rev Esp Enferm Dig. 2005;97:562–9.
8.
Zurück zum Zitat Ishikawa K, Matsumata T, Kishihara F, Fukayama Y, Masuda H. Laparoscopy-assisted distal gastrectomy for early gastric cancer with versus without prophylactic drainage. Surg Today. 2011;41:1049–53.CrossRef Ishikawa K, Matsumata T, Kishihara F, Fukayama Y, Masuda H. Laparoscopy-assisted distal gastrectomy for early gastric cancer with versus without prophylactic drainage. Surg Today. 2011;41:1049–53.CrossRef
9.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3). Gastric Cancer. 2011;14:238–44. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3). Gastric Cancer. 2011;14:238–44.
10.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver.4). Gastric Cancer. 2016;20:1–19.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver.4). Gastric Cancer. 2016;20:1–19.CrossRef
11.
Zurück zum Zitat Kanaya S, Gomi T, Momoi H, Tamaki N, Isobe H, Katayama T, Wada Y, Ohtoshi M. Delta-shaped anastomosis in totally laparoscopic Billroth I gastrectomy: new technique of intraabdominal gastroduodenostomy. J Am Coll Surg. 2002;195(2):284–7.CrossRef Kanaya S, Gomi T, Momoi H, Tamaki N, Isobe H, Katayama T, Wada Y, Ohtoshi M. Delta-shaped anastomosis in totally laparoscopic Billroth I gastrectomy: new technique of intraabdominal gastroduodenostomy. J Am Coll Surg. 2002;195(2):284–7.CrossRef
12.
Zurück zum Zitat Okabe H, Obama K, Tanaka E, Nomura A, Kawamura J, Nagayama S, Itami A, Watanabe G, Kanaya S, Sakai Y. Intracorporeal esophago-jejunal anastomosis after laparoscopic total gastrectomy for patients with gastric cancer. Surg Endosc. 2009;23(9):2167–71.CrossRef Okabe H, Obama K, Tanaka E, Nomura A, Kawamura J, Nagayama S, Itami A, Watanabe G, Kanaya S, Sakai Y. Intracorporeal esophago-jejunal anastomosis after laparoscopic total gastrectomy for patients with gastric cancer. Surg Endosc. 2009;23(9):2167–71.CrossRef
13.
Zurück zum Zitat Miura S, Kanaya S, Hosogi H, Kawada H, Akagawa S, Shimoike N, Okumura S, Okada T, Ito T, Arimoto A. Esophagojejunostomy with linear staplers in laparoscopic total gastrectomy: experience with 168 cases in 5 consecutive years. Surg Laparosc Endosc Percutan Tech. 2017;27:e101–7.CrossRef Miura S, Kanaya S, Hosogi H, Kawada H, Akagawa S, Shimoike N, Okumura S, Okada T, Ito T, Arimoto A. Esophagojejunostomy with linear staplers in laparoscopic total gastrectomy: experience with 168 cases in 5 consecutive years. Surg Laparosc Endosc Percutan Tech. 2017;27:e101–7.CrossRef
14.
Zurück zum Zitat Tanigawa N, Lee SW, Kimura T, Mori T, Uyama I, Nomura E, Okuda J, Konishi F. The endoscopic surgical skill qualification system for gastric surgery in Japan. Asian J Endosc Surg. 2011;4:112–5.CrossRef Tanigawa N, Lee SW, Kimura T, Mori T, Uyama I, Nomura E, Okuda J, Konishi F. The endoscopic surgical skill qualification system for gastric surgery in Japan. Asian J Endosc Surg. 2011;4:112–5.CrossRef
15.
Zurück zum Zitat Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billoth I gastrectomy. Surg Laparosc Endosc. 1994;4(2):146–8.PubMed Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billoth I gastrectomy. Surg Laparosc Endosc. 1994;4(2):146–8.PubMed
16.
Zurück zum Zitat Etoh T, Shiraishi N, Kitano S. Current trends of laparoscopic gastrectomy for gastric cancer in Japan. Asian J Endosc Surg. 2009;2:18–23.CrossRef Etoh T, Shiraishi N, Kitano S. Current trends of laparoscopic gastrectomy for gastric cancer in Japan. Asian J Endosc Surg. 2009;2:18–23.CrossRef
17.
Zurück zum Zitat Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M, Yamaue H, Yoshikawa T, Kojima K, the JCOG Gastric Cancer Surgical Study Group. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer. 2010;13:238–44.CrossRef Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M, Yamaue H, Yoshikawa T, Kojima K, the JCOG Gastric Cancer Surgical Study Group. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer. 2010;13:238–44.CrossRef
18.
Zurück zum Zitat Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report – a phase III multicenter, prospective, randomized trial (KLASS Trial). Ann Surg. 2010;251:417–20.CrossRef Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report – a phase III multicenter, prospective, randomized trial (KLASS Trial). Ann Surg. 2010;251:417–20.CrossRef
19.
Zurück zum Zitat Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, Koeda K, Yoshida K, Takagane A, Kojima K, Sakuramoto S, Shiraishi N, Kitano S. A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg. 2015;39(11):2734–41.CrossRef Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, Koeda K, Yoshida K, Takagane A, Kojima K, Sakuramoto S, Shiraishi N, Kitano S. A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg. 2015;39(11):2734–41.CrossRef
20.
Zurück zum Zitat Demange MK, Fregni F. Limits to clinical trials in surgical areas. Clinics (Sao Paulo). 2011;66(1):159–61.CrossRef Demange MK, Fregni F. Limits to clinical trials in surgical areas. Clinics (Sao Paulo). 2011;66(1):159–61.CrossRef
21.
Zurück zum Zitat Lonjon G, Boutron I, Trinquart L, Ahmad N, Aim F, Nizard R, Ravaud P. Comarison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. Ann Surg. 2014;259(1):18–25.CrossRef Lonjon G, Boutron I, Trinquart L, Ahmad N, Aim F, Nizard R, Ravaud P. Comarison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. Ann Surg. 2014;259(1):18–25.CrossRef
Metadaten
Titel
Laparoscopic gastrectomy with and without prophylactic drains in gastric cancer: a propensity score-matched analysis
verfasst von
Norihiro Shimoike
Shin Akagawa
Daisuke Yagi
Masazumi Sakaguchi
Yukinari Tokoro
Eiichiro Nakao
Takuya Tamura
Yusuke Fujii
Yuki Mochida
Yoshihisa Umemoto
Hidero Yoshimoto
Seiichiro Kanaya
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2019
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1690-9

Weitere Artikel der Ausgabe 1/2019

World Journal of Surgical Oncology 1/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.